A detailed history of Vanguard Group Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,739,039 shares of CLDX stock, worth $124 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,739,039
Previous 3,650,582 2.42%
Holding current value
$124 Million
Previous $153 Million 9.68%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$32.76 - $42.56 $2.9 Million - $3.76 Million
88,457 Added 2.42%
3,739,039 $138 Million
Q1 2024

May 10, 2024

BUY
$35.22 - $51.88 $21.3 Million - $31.3 Million
604,251 Added 19.84%
3,650,582 $153 Million
Q4 2023

Feb 14, 2024

BUY
$22.61 - $40.65 $9.67 Million - $17.4 Million
427,827 Added 16.34%
3,046,331 $121 Million
Q3 2023

Nov 14, 2023

BUY
$25.45 - $37.46 $526,509 - $774,972
20,688 Added 0.8%
2,618,504 $72.1 Million
Q2 2023

Aug 14, 2023

BUY
$30.29 - $38.28 $1.49 Million - $1.88 Million
49,218 Added 1.93%
2,597,816 $88.1 Million
Q1 2023

May 15, 2023

BUY
$34.78 - $47.43 $1.22 Million - $1.66 Million
35,034 Added 1.39%
2,548,598 $91.7 Million
Q4 2022

Feb 10, 2023

BUY
$27.78 - $45.38 $1.06 Million - $1.73 Million
38,183 Added 1.54%
2,513,564 $112 Million
Q3 2022

Nov 14, 2022

BUY
$22.7 - $37.57 $908,204 - $1.5 Million
40,009 Added 1.64%
2,475,381 $69.6 Million
Q2 2022

Aug 12, 2022

BUY
$20.5 - $37.33 $36,428 - $66,335
1,777 Added 0.07%
2,435,372 $65.7 Million
Q1 2022

May 13, 2022

BUY
$27.64 - $39.32 $567,697 - $807,593
20,539 Added 0.85%
2,433,595 $82.9 Million
Q4 2021

Feb 14, 2022

BUY
$35.68 - $56.27 $4.88 Million - $7.7 Million
136,857 Added 6.01%
2,413,056 $93.2 Million
Q3 2021

Nov 12, 2021

BUY
$28.95 - $55.99 $8.85 Million - $17.1 Million
305,793 Added 15.52%
2,276,199 $123 Million
Q2 2021

Aug 13, 2021

BUY
$20.71 - $35.37 $40.8 Million - $69.7 Million
1,970,406 New
1,970,406 $65.9 Million

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.55B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.